microRNA-135 a在阿尔茨海默病患者中的检测价值

摘要

Objective To evaluate the clinical value of microRNA-135a ( miR-135a ) in the detection of Alzheimer′s disease (AD).Methods The levels of miR-135a in mild cognitive impairment (MCI), dementia of Alzheimer′s type (DAT) and control group were tested.Results The miR-135a levels in cerebro-spinal fluid from MCI and DAT were significantly higher than those of control ( P<0.05), and it was lower in DAT group than that of MCI group(P<0.05).The miR-135a levels in serum from MCI and DAT were signifi-cantly lower than those of control(P<0.05), and it was lower in DAT group than that in MCI group(P<0.05).Furthermore, miR-135a might be a better marker than Aβ42 for early diagnosis of AD.Conclusions The serum miR-135a was a potential biomarker of AD, espe-cially for its early stage.%目的：初步探讨microRNA-135a（miR-135a）作为阿尔茨海默病（AD）生物标志物的潜在价值。方法使用实时定量 PCR检测痴呆期AD（DAT）患者、轻度认知障碍（MCI）患者和表面健康受试者血清和脑脊液中miR-135a含量。结果 MCI和DAT患者血清 miR-135a水平均低于对照组（P＜0.05），且DAT组低于MCI组（P＜0.05）；MCI和DAT患者脑脊液总体miR-135a水平均低于对照组（P＜0.05），且DAT组低于MCI组（P＜0.05）；且miR-135a对于早期AD的诊断价值可能优于Aβ42。结论血清miR-135a可能为AD，特别是早期AD诊断的标志物。